Rivian Automotive, Inc. vs Smith & Nephew plc — how do they compare? Rivian Automotive, Inc. trades at $16.06 (market cap $23.41B), while Smith & Nephew plc trades at $27.72 (market cap $11.63B). The key difference: Rivian Automotive, Inc. is far larger — about 2× Smith & Nephew plc's market cap, and Smith & Nephew plc pays a 2.85% dividend while Rivian Automotive, Inc. pays none. Which is the better fit depends on your goals.
| RIVN | SNN | |
|---|---|---|
Market Cap | $23.41B | $11.63B |
Sector | Consumer Cyclical | Health |
52-Week High | $22.45 | $38.53 |
52-Week Low | $12.50 | $27.80 |
Enterprise Value | $23.45B | $14.66B |
Dividend Yield | — | 2.85% |
Signals from Pluang's Aura AI — not financial advice
Rivian Automotive (RIVN) trades at $16.17, up 2.73% today, with a bullish technical signal from moving averages and a consensus analyst price target of $18.70. The company shows improving financial trends, with revenue growing to $5.39 billion in 2025 and narrowing net losses, though it remains unprofitable. Recent news highlights strong R2 SUV demand and production ramp-up, but cash flow remains negative, and the CFO departure adds execution risk.
RIVN presents a high-risk, high-reward opportunity for growth investors betting on its EV market execution. Upside hinges on successful R2 scaling and path to profitability, while risks include cash burn, competition, and macroeconomic pressures on EV demand. Analyst sentiment is cautiously optimistic with 48% buy ratings.
Smith & Nephew (SNN) trades at $27.87, down 3.46% over 24 hours and near its 52-week low. The stock shows a bearish technical trend with mixed sentiment; recent earnings have mostly beaten expectations, but Q2 2026 revenue growth missed and guidance was cut. Fundamentals are solid with revenue rising to $6.16B in 2025 and net income margin improving to 10.08%, though debt levels have increased. The company faces competitive pressures in key markets like U.S. Orthopaedics.
Outlook is cautious: valuation ratios like P/E of 18.96 are reasonable, but analyst consensus is Hold (65%) due to execution risks and CFO departure. Opportunities include innovation in surgical robotics and new product launches, but investors should monitor U.S. market weakness and debt management for sustained recovery.
Trailing returns across standard periods
Latest headlines on both assets
Rivian Automotive, Inc. is an automotive technology company. The Company designs and manufactures vans, trucks, and sports utility vehicles, as well as offers repair and maintenance services. Rivian Automotive serves customers in North America and the United Kingdom.
Read more on RIVN →Smith & Nephew designs, manufactures, and markets orthopedic devices, sports medicine and arthroscopic technologies, and wound-care solutions. Roughly 42% of the U.K.-based firm's revenue comes from orthopedic products, and another 30% is sports medicine and ENT. The remaining 28% of revenue is from the advanced wound therapy segment. Roughly half of Smith & Nephew's total revenue comes from the United States, just over 30% is from other developed markets, and emerging markets account for the remainder.
Read more on SNN →